BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38071082)

  • 1. [Research Progress in Treatment of Chronic Lymphocytic Leukemia --Review].
    Zhang R; Xin R; Dou LP; Jing Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1910-1915. PubMed ID: 38071082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
    Shadman M
    JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia.
    Iskierka-Jażdżewska E; Obracaj A; Urbaniak M; Robak T
    Curr Treat Options Oncol; 2022 Jun; 23(6):775-795. PubMed ID: 35357653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia.
    Zou Y; Xu W; Li J
    J Hematol Oncol; 2018 Nov; 11(1):130. PubMed ID: 30458878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs.
    Smolewski P; Robak T
    Acta Haematol; 2021; 144(4):365-379. PubMed ID: 33238270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.
    Griggio V; Perutelli F; Salvetti C; Boccellato E; Boccadoro M; Vitale C; Coscia M
    Front Immunol; 2020; 11():594556. PubMed ID: 33312177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review.
    Islam P
    Curr Treat Options Oncol; 2023 Sep; 24(9):1259-1273. PubMed ID: 37407887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapies in CLL.
    Park JH; Brentjens RJ
    Adv Exp Med Biol; 2013; 792():241-57. PubMed ID: 24014300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
    Small S; Ma S
    Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
    Odetola O; Ma S
    Curr Hematol Malig Rep; 2023 Oct; 18(5):130-143. PubMed ID: 37278884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia.
    Kovalovsky D; Yoon JH; Cyr MG; Simon S; Voynova E; Rader C; Wiestner A; Alejo J; Pittaluga S; Gress RE
    Leukemia; 2021 Sep; 35(9):2581-2591. PubMed ID: 33633313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging therapies for refractory chronic lymphocytic leukemia.
    Kutsch N; Hallek M; Eichhorst B
    Leuk Lymphoma; 2015 Feb; 56(2):285-92. PubMed ID: 24766469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.
    Kharfan-Dabaja MA; Kumar A; Hamadani M; Stilgenbauer S; Ghia P; Anasetti C; Dreger P; Montserrat E; Perales MA; Alyea EP; Awan FT; Ayala E; Barrientos JC; Brown JR; Castro JE; Furman RR; Gribben J; Hill BT; Mohty M; Moreno C; O'Brien S; Pavletic SZ; Pinilla-Ibarz J; Reddy NM; Sorror M; Bredeson C; Carpenter P; Savani BN
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2117-2125. PubMed ID: 27660167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
    Maddocks K; Jones JA
    Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia.
    Hus I; Salomon-Perzyński A; Robak T
    Expert Opin Biol Ther; 2020 Jul; 20(7):799-812. PubMed ID: 32090643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic Lymphocytic Leukemia (CLL): Biology and Therapy.
    Siddiqi T
    Cancer Treat Res; 2021; 181():133-149. PubMed ID: 34626359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulation and immune reconstitution in chronic lymphocytic leukemia.
    Riches JC; Gribben JG
    Semin Hematol; 2014 Jul; 51(3):228-34. PubMed ID: 25048786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
    Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.